It's not uncommon for biotechs to go quiet for long stretches of time, particularly when they are basically one-product companies with little incremental data on the way. In the case of YM Biosciences (YMI), though, shareholders have reason to be a little edgy about the lack of news. Not only has the company been cagey in discussing its plans for pivotal trials of its lead drug CYT387, but partnership discussions have supposedly been ongoing for most of the year so far. While I'm cautiously optimistic that YM Biosciences does have a real winner in myelofibrosis, it may well be hard for this stock to outperform without the seal of approval represented by a Big Pharma partner.
Please click here for more:
The Wait Goes On At YM Biosciences